Open access, Immunotherapy Biomarkers

Neutrophil-epithelial niches arrest B-cell maturation in dysfunctional tertiary lymphoid structures of gastric cancer neoadjuvant immunochemotherapy

20 de October de 2026 by Wei, C., Fu, Q., Wei, H., Zhai, H., Dong, S., Ma, X., Bie, L., Ma, Y., Wang, Y., Xia, Q., Luo, S., Li, N.

Distinct genomic landscapes of mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancer depending on tumor mutation burden (TMB) levels

15 de October de 2026 by

Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy

14 de October de 2026 by Yu, Y., Liu, Y., Zhang, X., Yang, W., Hou, S., Yu, W., Zhang, F., Yu, B., Hu, Z., Wu, Z., Huang, S., Wang, J.

AI-derived 3D body composition predicts prognosis of chemoimmunotherapy in small cell lung cancer: a multicenter study

12 de October de 2026 by

TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy

7 de October de 2026 by

Background
Identifying robust predictive biomarkers for immune checkpoint blockade (ICB) remains a challenge. While alternative splicing (AS) shapes tumor immunity, the lack of large-scale, consensus-based datasets constrains the characterization of I…

METLUNG: plasma metabolomic profiling identifies metabolomic signatures associated with immunotherapy outcomes in non-small cell lung cancer

25 de September de 2026 by

Background
Identifying reproducible biomarkers associated with treatment outcomes remains a major unmet clinical need in advanced non-small cell lung cancer (NSCLC). METLUNG evaluated whether plasma metabolomic profiling, alone or combined with clinic…

Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort

12 de September de 2026 by Yu, H., Li, X., Cheng, X., Deng, Y., Wang, Y., Li, Y., Liu, B., Huang, Z., Cao, D.

Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Tertiary lymphoid structures (TLS) have emerged as key components of the tumor immune microenvironment, associated with improved survival and enhanced immu…

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer

12 de September de 2026 by

Background
Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunothera…

PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype

9 de September de 2026 by Wang, Q., Chen, Y., Huang, D., Wu, H., Wu, T., Han, Y., Cai, C., Li, J., Shao, Y., Ruan, J., Jiang, H.

Background
Gastric cancer (GC) derives limited benefit from immunotherapy, with clinical responses observed in only a minority of patients. Increasing evidence suggests that heterogeneity within the tumor immune microenvironment (TME) is a critical de…

Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities

7 de September de 2026 by

Background
Immune-related adverse events (irAEs) post-immune checkpoint blockade (ICB) are a leading cause of patient morbidity. Robust peripheral biomarkers of irAEs are required to improve patient stratification to existing treatment regimens, and t…